Form 4: ZyVersa Therapeutics Director and 10% Owner James Sapirstein Granted 11,066 Stock Options

ZyVersa Therapeutics, Inc. Director and 10% Owner James Sapirstein was granted 11,066 stock options with an exercise price of $0.59, vesting over three years.

Summary

• James Sapirstein, a Director and 10% owner of ZyVersa Therapeutics, Inc. (ZVSA), was granted 11,066 stock options.
• The options have an exercise price of $0.59 per share.
• The grant date for these options is July 11, 2025.
• The options will vest and become exercisable in equal annual installments on the first three anniversaries of the grant date.
• Vesting is contingent upon Mr. Sapirstein's continued service on each vesting date.
• The options expire on July 11, 2035.

Sentiment

Score: 6

Explanation: The document reports a standard equity grant to a director, which is generally a neutral to slightly positive event as it aligns interests. There are no negative financial disclosures or operational issues reported.

Positives

• Granting stock options to a director and 10% owner aligns their interests with long-term shareholder value, as the options gain value if the stock price increases above the exercise price.
• The vesting schedule over three years encourages continued service and commitment from a key board member.

Negatives

• The exercise price of $0.59 is relatively low, which could suggest a low current stock valuation or be part of a compensation package designed to incentivize significant future growth from a low base.
• The transaction date for the option grant is July 11, 2025, which is a future date, indicating a pre-planned grant being reported.

Risks

• The value of the options is entirely dependent on the future performance of ZyVersa Therapeutics' stock price; if the stock price does not rise above the exercise price of $0.59, the options may expire worthless.
• The vesting of the options is subject to the director's continued service, meaning Mr. Sapirstein must remain with the company for the options to fully vest.

Future Outlook

The document primarily reports a specific equity transaction and does not contain explicit forward-looking statements or guidance regarding company performance, strategic initiatives, or financial projections, beyond the vesting schedule of the options.

Industry Context

Granting stock options to directors is a common practice in the biotechnology and pharmaceutical industries, particularly for companies like ZyVersa Therapeutics, which may be in development stages. This compensation method aligns director incentives with long-term company growth and shareholder value, a standard approach to attract and retain experienced board members in a competitive sector.

Comparison to Industry Standards

• The practice of granting stock options to directors is a standard compensation mechanism across publicly traded companies, especially in growth-oriented sectors like biotechnology.
• The vesting schedule over three years is typical for equity grants to ensure long-term commitment and alignment with company performance.
• The exercise price of $0.59 would need to be compared against ZyVersa Therapeutics' stock price on the grant date (July 11, 2025) to assess if it was at-the-money, in-the-money, or out-of-the-money. Typically, options are granted at the market price on the grant date.
• The number of options granted (11,066) would be evaluated in the context of the director's overall compensation package and the company's total outstanding shares to determine its significance relative to peer companies.

Related Party Transactions

• Grant of 11,066 stock options to James Sapirstein, a Director and 10% owner of ZyVersa Therapeutics, Inc., with an exercise price of $0.59.

Stakeholder Impact

• Shareholders: The grant aligns the director's interests with shareholders by incentivizing stock price appreciation. Potential dilution from option exercise is a long-term consideration, but the number of options is relatively small.
• Employees: No direct impact on general employees is mentioned.
• Customers/Suppliers/Creditors: No direct impact on these stakeholders is mentioned.

Next Steps

• The options will vest in equal annual installments on the first three anniversaries of the July 11, 2025 grant date.
• Mr. Sapirstein's continued service to the company is required for the options to vest.

Key Dates

Recommendation

Keywords

ZyVersa Therapeutics, ZVSA, Stock Options, Form 4, Beneficial Ownership, Director Compensation, Equity Grant, Insider Transaction, James Sapirstein